NCT04311411View on ClinicalTrials.gov

A Study of Tirzepatide in Overweight and Very Overweight Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

August 24, 2020

Primary Completion Date

December 16, 2022

Study Completion Date

December 16, 2022

Conditions
ObesityOverweight
Interventions
DRUG

Tirzepatide

Administered SC.

DRUG

Placebo

Administered SC.

DRUG

Liraglutide

Administered SC.

Trial Locations (3)

21287

Johns Hopkins University School of Medicine, Baltimore

46202

Indiana University School of Medicine, Indianapolis

70808

Pennington Biomedical Research Center, Baton Rouge

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04311411 - A Study of Tirzepatide in Overweight and Very Overweight Participants | Biotech Hunter | Biotech Hunter